Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection

被引:59
|
作者
Brinck, Jonas W. [1 ,6 ]
Thomas, Aurelien [2 ,3 ]
Lauer, Estelle [2 ]
Jornayvaz, Francois R. [1 ]
Brulhart-Meynet, Marie-Claude [1 ]
Prost, Jean-Christophe [2 ]
Pataky, Zoltan [4 ,5 ]
Lofgren, Patrik [6 ]
Hoffstedt, Johan [6 ]
Eriksson, Mats
Pramfalk, Camilla [7 ,8 ]
Morel, Sandrine [9 ]
Kwak, Brenda R. [9 ]
van Eck, Miranda [6 ,10 ]
James, Richard W. [1 ]
Frias, Miguel A. [1 ]
机构
[1] Univ Geneva, Dept Internal Med, Fac Med, Div Endocrinol Diabetol Hypertens & Nutr, Geneva, Switzerland
[2] Univ Ctr Legal Med, Toxicol Unit, Lausanne, Switzerland
[3] Univ Lausanne, Univ Lausanne Hosp, Fac Biol & Med, Lausanne, Switzerland
[4] Univ Hosp Geneva, Serv Therapeut Educ Chron Dis, Dept Community Med, WHO Collaborating Ctr, Geneva, Switzerland
[5] Univ Geneva, Geneva, Switzerland
[6] Karolinska Inst, Dept Med, Stockholm, Sweden
[7] Karolinska Inst, Dept Biosci & Nutr, Mol Nutr Unit, Stockholm, Sweden
[8] Karolinska Inst, Dept Lab Med, Div Clin Chem, Stockholm, Sweden
[9] Univ Geneva, Fac Med, Dept Pathol & Immunol, Geneva, Switzerland
[10] Leiden Univ, Div Biopharmaceut Cluster BioTherapeut, Leiden Acad Ctr Drug Res, Leiden, Netherlands
基金
瑞士国家科学基金会;
关键词
AGE; cardiomyocytes; glycation; HDL; ischemia reperfusion injury; sphingosine-1-phosphate; type 2 diabetes mellitus; GLYCATION END-PRODUCTS; APOLIPOPROTEIN M; SPHINGOSINE; 1-PHOSPHATE; HIGH-RISK; HDL; DYSLIPIDEMIA; SERUM; PARTICLES; RECEPTOR; REVEALS;
D O I
10.1161/ATVBAHA.115.307049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-The dyslipidemia of type 2 diabetes mellitus has multiple etiologies and impairs lipoprotein functionality, thereby increasing risk for cardiovascular disease. High-density lipoproteins (HDLs) have several beneficial effects, notably protecting the heart from myocardial ischemia. We hypothesized that glycation of HDL could compromise this cardioprotective effect. Approach and Results-We used in vitro (cardiomyocytes) and ex vivo (whole heart) models subjected to oxidative stress together with HDL isolated from diabetic patients and nondiabetic HDL glycated in vitro (methylglyoxal). Diabetic and in vitro glycated HDL were less effective (P<0.05) than control HDL in protecting from oxidative stress. Protection was significantly, inversely correlated with the degree of in vitro glycation (P<0.001) and the levels of hemoglobin A1c in diabetic patients (P<0.007). The ability to activate protective, intracellular survival pathways involving Akt, Stat3, and Erk1/2 was significantly reduced (P<0.05) using glycated HDL. Glycation reduced the sphingosine-1-phosphate (S1P) content of HDL, whereas the S1P concentrations of diabetic HDL were inversely correlated with hemoglobin A1c (P<0.005). The S1P contents of in vitro glycated and diabetic HDL were significantly, positively correlated (both <0.01) with cardiomyocyte survival during oxidative stress. Adding S1P to diabetic HDL increased its S1P content and restored its cardioprotective function. Conclusions-Our data demonstrate that glycation can reduce the S1P content of HDL, leading to increased cardiomyocyte cell death because of less effective activation of intracellular survival pathways. It has important implications for the functionality of HDL in diabetes mellitus because HDL-S1P has several beneficial effects on the vasculature.
引用
收藏
页码:817 / 824
页数:8
相关论文
共 50 条
  • [31] Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses
    Jia, Lianqun
    Long, Shiyin
    Fu, Mingde
    Yan, Bingyu
    Tian, Ying
    Xu, Yanhua
    Gou, Lantu
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (09): : 1141 - 1148
  • [32] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
    SHAW, P
    MEDICAL JOURNAL OF AUSTRALIA, 1979, 1 (01) : 24 - 24
  • [33] High-Density Lipoprotein Infusions
    Takata, Kohei
    Di Bartolo, Belinda A.
    Nicholls, Stephen J.
    CARDIOLOGY CLINICS, 2018, 36 (02) : 311 - +
  • [34] Assembly of high-density lipoprotein
    Yokoyama, S
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) : 20 - 27
  • [35] HIGH-DENSITY LIPOPROTEIN IN OCTOGENARIANS
    RON, D
    AVIRAM, M
    BROOK, JG
    BIOCHEMICAL MEDICINE, 1983, 30 (02): : 253 - 260
  • [36] HIGH-DENSITY LIPOPROTEIN AND ATHEROSCLEROSIS
    HARVENGT, C
    ACTA CLINICA BELGICA, 1978, 33 (02): : 73 - 77
  • [37] Dysfunctional high-density lipoprotein
    Feng, Hong
    Li, Xiang-An
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) : 156 - 162
  • [38] HIGH-DENSITY LIPOPROTEIN QUANTITATION
    ALBERS, JJ
    WARNICK, GR
    CHEUNG, MC
    JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 1978, 55 (03) : A234 - A234
  • [39] HIGH-DENSITY LIPOPROTEIN METABOLISM
    NICOLL, A
    MILLER, NE
    LEWIS, B
    ADVANCES IN LIPID RESEARCH, 1980, 17 : 53 - 106
  • [40] Raising high-density lipoprotein
    Wierzbicki, AS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (09) : 817 - 819